<DOC>
	<DOC>NCT00087984</DOC>
	<brief_summary>The purpose of this trial is to examine the safety, feasibility, immunological response, and clinical antitumor activity of administering a dendritic cell vaccine to patients with metastatic renal cell carcinoma.</brief_summary>
	<brief_title>RNA-Loaded Dendritic Cell Cancer Vaccine</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Renal Cell</mesh_term>
	<criteria>Have a new diagnosis of metastatic renal cell carcinoma; Must be at least 18 years or older; Have a scheduled unilateral nephrectomy; ECOG of 0 or 1; Free of brain metastases by CT or MRI; Normal renal function in contralateral kidney; Male or nonpregnant/nonlactating female on appropriate birth control methods while on study; Clinically acceptable screening results. No immunosuppressive therapy not limited to corticosteroids (including topical steroids or steroid containing inhalers), azathioprine cyclosporine two months prior to study entry; No active autoimmune disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Kidney cancer</keyword>
	<keyword>Renal cancer</keyword>
</DOC>